Conferences
ASCO 2019 /
Understanding eligibility criteria for clinical trials to increase study size
31st May - 4th Jun 2019
Dr R. Donald Harvey talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about a study looking at aNSCLC patients from ASCO’s CancerLinQ database and understanding their eligibility criteria.
He explains that three main areas were considered in the criteria: the presence or absence of brain metastases, prior or concurrent history of additional cancer diagnosis and the renal function.
Dr Harvey reports that the percentage of patients excluded was 47.7% for the older, restrictive criteria and 1.5% when the criteria was taken away.
Watch the press conference here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Categories:
Lung & pleura · Nutrition & wellbeing · Care · Global health & cancer · Organisation of cancer · R&D · Regulatory · Science domains · Social determinants · Technology & innovation · Training & development · Biology · ASCO 2019Disease areas
Patient Care
Policy
Prevention & Screening
Founding partners
Founding Charities
Published by
